💊Kyowa Hakko Kirin Announces Discontinuation for Developing ARQ 197 (Tivantinib)

By JPN, Pharmaceutical

💊Kyowa Hakko Kirin Announces Discontinuation for Developing ARQ 197 (Tivantinib)

http://www.kyowa-kirin.com/news_releases/2017/pdf/e20171006_01.pdf

More from tokioX :

  1. Kyowa Kirin Announces FDA Approval of NOURIANZTM (istradefylline) for Use in Parkinson’s Disease
  2. 💊Fujifilm Kyowa Kirin Biologics与Mylan合作将Humira®生物仿制药商业化（adalimumab）
  3. 💊FDA & PHARMA TODAY
  4. 💊Pharma – News Releases
  5. 💊Kyowa Hakko Kirin, anti-Ccr4 humanized antibody acceptance application for European approval of Mogum Lysumab  20171027
  6. 💊Kyowa Hakko Kirin Announces the Intent to File Istradefylline (KW-6002) for Parkinson’s Disease with the US FDA
  7. 💊Kyowa Hakko Kirin News、Ultragenyx and Kyowa Hakko Kirin Announce FDA Acceptance and Priority Review Designation of Burosumab’s Biologics License Application 20171010